美邦股份:股价异常波动,业绩下滑与涨幅偏离引风险提示

Core Viewpoint - The company announced that its stock experienced abnormal fluctuations, with a cumulative price deviation exceeding 20% over three consecutive trading days in February 2026 [1] Financial Performance - For the first three quarters of 2025, the company reported revenue of 609 million, a year-on-year decrease of 2.23% [1] - The net profit for the same period was 36.1961 million, reflecting a year-on-year decline of 16.36% [1] Stock Performance - From February 10 to 24, the company's stock hit the daily limit for four consecutive days, resulting in a total increase of 46.43%, outperforming both the Shanghai Composite Index and the "agricultural chemical products" industry [1] - The latest rolling price-to-earnings (P/E) ratio for the company is 143.19, significantly higher than the industry average of 33.99 [1] Investor Advisory - The company has reminded investors to be cautious regarding risks associated with stock price, performance, and P/E ratio [1]

Shaanxi Meibang Pharmaceutical -美邦股份:股价异常波动,业绩下滑与涨幅偏离引风险提示 - Reportify